IS8319A - N-staðgengnir bensimidasólýl c-kit tálmar - Google Patents
N-staðgengnir bensimidasólýl c-kit tálmarInfo
- Publication number
- IS8319A IS8319A IS8319A IS8319A IS8319A IS 8319 A IS8319 A IS 8319A IS 8319 A IS8319 A IS 8319A IS 8319 A IS8319 A IS 8319A IS 8319 A IS8319 A IS 8319A
- Authority
- IS
- Iceland
- Prior art keywords
- substituted benzimidazolyl
- kit inhibits
- inhibits
- kit
- benzimidazolyl
- Prior art date
Links
- -1 N-substituted benzimidazolyl Chemical group 0.000 title 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49680603P | 2003-08-21 | 2003-08-21 | |
| PCT/US2004/026482 WO2005021531A1 (en) | 2003-08-21 | 2004-08-16 | N-substituted benzimidazolyl c-kit inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8319A true IS8319A (is) | 2006-02-21 |
Family
ID=34272519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8319A IS8319A (is) | 2003-08-21 | 2006-02-21 | N-staðgengnir bensimidasólýl c-kit tálmar |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7521448B2 (is) |
| EP (1) | EP1664021A1 (is) |
| JP (1) | JP4769720B2 (is) |
| KR (1) | KR20060121818A (is) |
| CN (1) | CN1852905A (is) |
| AP (1) | AP2006003549A0 (is) |
| AR (1) | AR045387A1 (is) |
| AU (1) | AU2004268949A1 (is) |
| BR (1) | BRPI0413746A (is) |
| CA (1) | CA2535896A1 (is) |
| IL (1) | IL173614A0 (is) |
| IS (1) | IS8319A (is) |
| MX (1) | MXPA06002018A (is) |
| NO (1) | NO20060664L (is) |
| RU (1) | RU2006108803A (is) |
| TW (1) | TW200524905A (is) |
| UA (1) | UA82395C2 (is) |
| WO (1) | WO2005021531A1 (is) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| US7442709B2 (en) * | 2003-08-21 | 2008-10-28 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine c-Kit inhibitors |
| WO2005044788A1 (ja) * | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
| ATE428421T1 (de) * | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| AR052419A1 (es) | 2004-12-01 | 2007-03-21 | Osi Pharm Inc | Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit |
| JP2008534683A (ja) * | 2005-04-04 | 2008-08-28 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 過剰増殖性疾患の治療のためのピロロ［２，３−ｄ］イミダゾール |
| DE602006007976D1 (de) * | 2005-04-13 | 2009-09-03 | Neurosearch As | Benzimidazolderivate und deren verwendung zur modulation des gabaa-rezeptorkomplexes |
| GB0507575D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| US7776900B2 (en) * | 2005-04-19 | 2010-08-17 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex |
| WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| CN101316590B (zh) | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
| DE602006010602D1 (de) * | 2005-12-05 | 2009-12-31 | Neurosearch As | Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes |
| TW200740776A (en) * | 2006-02-06 | 2007-11-01 | Osi Pharm Inc | N-phenylbenzotriazolyl c-kit inhibitors |
| WO2007136103A1 (ja) * | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
| KR101472600B1 (ko) * | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| US7977338B2 (en) | 2006-10-16 | 2011-07-12 | Novartis Ag | Phenylacetamides being FLT3 inhibitors |
| JP5442449B2 (ja) * | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| EP2114941B1 (en) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| KR20090108086A (ko) * | 2007-01-19 | 2009-10-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 췌장암 치료용 조성물 |
| EP2119707B1 (en) * | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| EP1997381A1 (en) * | 2007-06-01 | 2008-12-03 | Commissariat à l'Energie Atomique | Use of a compound having a monogalactosyldiacylglycerol synthase inhibitory activity as herbicide or algaecide, herbicide and algaecide compositions |
| CN101821253B (zh) | 2007-08-31 | 2013-07-17 | 安斯泰来制药有限公司 | 哌啶衍生物 |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0720041D0 (en) * | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| CN101848895B (zh) * | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| US20100324087A1 (en) * | 2008-01-29 | 2010-12-23 | Eisai R&D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| US20110030037A1 (en) * | 2009-07-07 | 2011-02-03 | Vadim Olshansky | Zone migration in network access |
| BR112012003592B8 (pt) | 2009-08-19 | 2021-05-25 | Eisai R&D Man Co Ltd | composição farmacêutica contendo derivado de quinolina |
| CA2791020A1 (en) * | 2010-04-28 | 2011-11-03 | Daiichi Sankyo Company, Limited | [5,6] heterocyclic compound |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| EP2700403B1 (en) | 2011-04-18 | 2015-11-25 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
| WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| UA111382C2 (uk) * | 2011-10-10 | 2016-04-25 | Оріон Корпорейшн | Інгібітори протеїнкінази |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| JP2016520532A (ja) * | 2013-03-15 | 2016-07-14 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | ベンゾイミダゾール誘導体およびその使用 |
| TWI628176B (zh) * | 2013-04-04 | 2018-07-01 | 奧利安公司 | 蛋白質激酶抑制劑 |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| CA2957005C (en) | 2014-08-28 | 2021-10-12 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| SG11201706630UA (en) | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EA201991197A1 (ru) * | 2016-12-15 | 2020-01-13 | Ариад Фармасьютикалз, Инк. | БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| WO2020135878A1 (zh) * | 2018-12-29 | 2020-07-02 | 南京明德新药研发有限公司 | 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202415646A (zh) * | 2022-08-01 | 2024-04-16 | 日商模數探索股份有限公司 | Kit抑制劑、化合物、醫藥組合物、及其使用方法 |
| WO2024117179A1 (en) * | 2022-11-30 | 2024-06-06 | Alivexis, Inc. | Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| BE788751A (fr) | 1971-09-13 | 1973-01-02 | Teijin Ltd | Membranes polymeres permselectives |
| GB8610980D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Heterocyclic fused tricyclic compounds |
| US5111688A (en) | 1988-01-22 | 1992-05-12 | Measurex Corporation | Device and method for calibrating a non-destructive sheet strength measuring system |
| DK40192D0 (da) | 1992-03-26 | 1992-03-26 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| KR970701182A (ko) | 1994-02-10 | 1997-03-17 | 스피겔 알렌 제이 | 벤조다이아제핀 수용체 부위의 작용물질 및 길항물질로서의 5-헤테로아릴인돌 유도체(5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists) |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| US5972980A (en) | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6001866A (en) | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| NZ334868A (en) * | 1996-10-21 | 2001-02-23 | Neurosearch As | 1-Phenyl-benzimidazole compounds and their use as BAGA-a receptor modulators |
| DE69727199T2 (de) | 1996-12-09 | 2004-11-18 | Pfizer Inc. | Benzimidazol-Verbindungen |
| US6414008B1 (en) | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
| RU2199532C2 (ru) | 1997-06-27 | 2003-02-27 | Фудзисава Фармасьютикал Ко., Лтд. | Сульфонамидное соединение |
| US5990146A (en) * | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO1999055679A1 (en) | 1998-04-28 | 1999-11-04 | Trega Biosciences, Inc. | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| WO2000006549A1 (en) | 1998-07-28 | 2000-02-10 | Nihon Nohyaku Co., Ltd. | Fused-heterocycle dicarboxylic diamide derivatives or salts thereof, herbicides and usage thereof |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| US6348032B1 (en) | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
| US6329383B1 (en) | 1999-01-25 | 2001-12-11 | Pharmacia Ab | 2-amino-5-pyrimidine acetic acid compounds |
| US6281237B1 (en) | 1999-04-02 | 2001-08-28 | Neurogen Corporation | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives |
| CO5190696A1 (es) | 1999-06-16 | 2002-08-29 | Smithkline Beecham Corp | Antagonistas de los receptores il-8 |
| AU5636900A (en) * | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| JP2003503354A (ja) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | Ｓｒｃキナーゼ阻害剤化合物 |
| WO2001000207A1 (en) * | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US6534535B1 (en) | 1999-08-12 | 2003-03-18 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6512000B1 (en) | 1999-08-20 | 2003-01-28 | Boehringer Ingelheim Pharma Kg | Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity |
| DE60016858T2 (de) | 1999-09-13 | 2005-12-08 | Eastman Kodak Co. | Photographisches Material mit verbesserter Farbwiedergabe |
| US6316474B1 (en) | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| WO2001057019A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
| EP1255750A1 (en) | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US20020128232A1 (en) | 2000-10-12 | 2002-09-12 | Henderson Scott A. | Heterocyclic angiogenesis inhibitors |
| AU2002221566A1 (en) | 2000-12-20 | 2002-07-01 | Neurosearch A/S | Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders |
| GB0102109D0 (en) | 2001-01-26 | 2001-03-14 | Syngenta Ltd | Chemical process |
| JP2004523565A (ja) | 2001-03-05 | 2004-08-05 | トランス テック ファーマ，インコーポレイテッド | 治療因子としてのベンゾイミダゾール誘導体 |
| US20030109714A1 (en) | 2001-03-22 | 2003-06-12 | Neil Wishart | Transition metal mediated process |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| AUPS251402A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Kinase inhibitors |
| CA2486187C (en) | 2002-05-23 | 2013-02-19 | Cytopia Pty Ltd. | Kinase inhibitors |
| PL375532A1 (en) * | 2002-08-08 | 2005-11-28 | Smithkline Beecham Corporation | Benzimidazol-1-yl-thiophene compounds for the treatment of cancer |
-
2004
- 2004-08-16 WO PCT/US2004/026482 patent/WO2005021531A1/en not_active Ceased
- 2004-08-16 MX MXPA06002018A patent/MXPA06002018A/es unknown
- 2004-08-16 KR KR1020067003585A patent/KR20060121818A/ko not_active Withdrawn
- 2004-08-16 US US10/921,414 patent/US7521448B2/en not_active Expired - Fee Related
- 2004-08-16 CA CA002535896A patent/CA2535896A1/en not_active Abandoned
- 2004-08-16 RU RU2006108803/04A patent/RU2006108803A/ru not_active Application Discontinuation
- 2004-08-16 JP JP2006523955A patent/JP4769720B2/ja not_active Expired - Fee Related
- 2004-08-16 CN CNA2004800240461A patent/CN1852905A/zh active Pending
- 2004-08-16 BR BRPI0413746-9A patent/BRPI0413746A/pt not_active IP Right Cessation
- 2004-08-16 AP AP2006003549A patent/AP2006003549A0/xx unknown
- 2004-08-16 UA UAA200602942A patent/UA82395C2/uk unknown
- 2004-08-16 EP EP04781204A patent/EP1664021A1/en not_active Withdrawn
- 2004-08-16 AU AU2004268949A patent/AU2004268949A1/en not_active Abandoned
- 2004-08-20 TW TW093125230A patent/TW200524905A/zh unknown
- 2004-08-20 AR ARP040103008A patent/AR045387A1/es not_active Application Discontinuation
-
2006
- 2006-02-08 IL IL173614A patent/IL173614A0/en unknown
- 2006-02-10 NO NO20060664A patent/NO20060664L/no not_active Application Discontinuation
- 2006-02-21 IS IS8319A patent/IS8319A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007502821A (ja) | 2007-02-15 |
| WO2005021531A1 (en) | 2005-03-10 |
| RU2006108803A (ru) | 2007-09-27 |
| TW200524905A (en) | 2005-08-01 |
| UA82395C2 (en) | 2008-04-10 |
| CA2535896A1 (en) | 2005-03-10 |
| EP1664021A1 (en) | 2006-06-07 |
| BRPI0413746A (pt) | 2006-10-24 |
| NO20060664L (no) | 2006-05-16 |
| AP2006003549A0 (en) | 2006-04-30 |
| AR045387A1 (es) | 2005-10-26 |
| IL173614A0 (en) | 2006-07-05 |
| CN1852905A (zh) | 2006-10-25 |
| KR20060121818A (ko) | 2006-11-29 |
| MXPA06002018A (es) | 2006-05-31 |
| US7521448B2 (en) | 2009-04-21 |
| AU2004268949A1 (en) | 2005-03-10 |
| JP4769720B2 (ja) | 2011-09-07 |
| US20060189629A1 (en) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004017623D1 (de) | N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitoren | |
| IL173614A0 (en) | N-substituted benzimidazolyl c-kit inhibitors | |
| IS7667A (is) | Nýjar bensimídazólafleiður | |
| IS8318A (is) | N3-staðgengnir imidasópýridín c-kit tálmar | |
| ATE499347T1 (de) | Amidderivate | |
| ATE340782T1 (de) | Piperidinbenzolsulfonamidderivate | |
| DK1611131T3 (da) | Pyrazolopyridin-derivater | |
| ATE352550T1 (de) | Chinazolinderivate | |
| ATE386518T1 (de) | Benzimidazolderivate | |
| ATE420066T1 (de) | Amidoacetonitrilderivate | |
| IL199668A0 (en) | New benzimidazole derivatives | |
| DK1606277T3 (da) | Imidazol-4-yl-ethynyl-pyridinderivater | |
| DE602004019555D1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone | |
| DK1652843T3 (da) | Amidderivater | |
| ATE354365T1 (de) | N-thiazol-2-yl-benzamid-derivate | |
| IS8091A (is) | Hringtengd bensimídasól | |
| DK1706373T3 (da) | Amidoacetonitrilderivater | |
| DE502004003823D1 (de) | Kran | |
| IS8045A (is) | Púrín-6-ón-afleiður | |
| EP1549104A4 (en) | Speaker device | |
| NO20030752L (no) | Bolgedempningsanordning | |
| ATE514681T1 (de) | N-substituierte pyrazolylcarboxanilide | |
| DE602004018293D1 (de) | Fahrwerkanordnung | |
| DE602004003965D1 (de) | Halogenalkyl- und piperidinsubstituierte benzimidazolderivate | |
| IS8446A (is) | Staðgengin bensimidasól-, benstríasól- og bensimidasólon-o-glúkósíð |